Compounded tirzepatide availability tracker — June 2026

JenPlateau said:

Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

JenPlateau has the substance of this right. The condition it depends on is worth stating. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

marcus_mpls said:

Agreed on the mechanism, with the caveat that the head-to-head used semaglutide 1mg, not 2.4mg.

Saving this. It is the first explanation that did not require me to already understand it.

JenPlateau said:

Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Pushing back on JenPlateau here. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

The figures, for anyone assembling their own picture. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here.